



# White Water Rafting: Navigating the Lymph Rapids

Bruce Kaufman, DO/MPH; Mary Pickett, MD

Department of Medicine, Oregon Health & Science University, Portland, OR

## Introduction

- Chylous ascites is a rare form of ascites characterized by lymph accumulation in the peritoneal cavity.<sup>1,2</sup>
- Although typically responsive to conservative therapy, refractory cases are difficult to manage and burdensome to affected patients.

## Case Presentation

### HPI:

- A 75-year-old male underwent left-sided radical nephrectomy with regional lymphadenectomy for metastatic renal cell carcinoma.
- Three weeks later, he presented with anasarca, acute renal failure, and ascites complicated by hypoxemic respiratory failure. On admission, he reported severe diffuse abdominal pain and distension.

### Past Medical History:

- T2N1M0 renal cell carcinoma
- Type 2 Diabetes Mellitus
- Chronic Kidney Disease, Stage III

### Past Surgical History:

- Left-sided radical nephrectomy with regional lymphadenectomy

### Vitals/Exam:

- Afebrile, HR 78, BP 113/69, RR 21, SpO2 99% 2L NC.
- Obese elderly white male, no acute distress, anasarca, tense distended abdomen with positive fluid wave

**Labs:** Initial paracentesis confirmed milky ascites with triglycerides >800 mg/dL. Additional chemistries noted Na=130 mmol/L, BUN=85 mg/dL, and serum creatinine=3.5 mg/dL.

## Hospital Course and Clinical Follow-Up

- A high-protein, low fat diet permitting medium chain triglycerides and adjunctive octreotide 150 mg IV every 8 hours were initiated. Rapid accumulation of chylous ascites persisted.
- Serial large volume paracenteses were required every 2-4 days for symptomatic relief. Multiple episodes of suspected SBP were empirically treated.
- Subsequent lymphangiography demonstrated a 2 mm chylous leak at L3. Interventional radiology unsuccessfully attempted CT-guided lymphatic glue embolization twice.
- An eight-week trial of absolute fasting with total parenteral nutrition (TPN) was recommended and attempted prior to considering surgical exploration.
- After an eight-week fasting trial failed, urology performed robotic laparoscopic exploratory laparotomy and chylous leak repair. Multiple chylous leaks were ligated with a 90% reduction in flow.
- Subsequent abdominal ultrasounds revealed trace ascites. Our patient returned to enteral feeding with TPN calorie supplementation prior to discharge to a long-term acute care hospital two weeks later.



Triglyceride-rich “milky-appearing” chylous ascites

Lymphangiography demonstrating leakage of lipiodiol contrast (arrow) at the L3 level confirming the chylous leak

## Discussion

- Clinical manifestations of chylous ascites range from abdominal pain to malnutrition and immunologic deficits.<sup>1</sup>
- A paracentesis demonstrating triglyceride-rich milky-appearing ascites is diagnostic.
- Lymphangiography often (up to 86% of the time) confirms the source and severity of a chylous leak.<sup>1</sup>
- Chylous ascites is **most commonly due to malignancy or cirrhosis in adults**. Other causes include congenital anomalies, trauma, infections, inflammatory conditions, and **iatrogenic injury** from AAA repairs and **oncologic abdominal surgeries**.<sup>1,2</sup>

## Teaching Points

- **Most lymphatic leaks seal spontaneously** if a low-flow state is present. Conservative therapies aim to reduce lymphatic flow.<sup>2</sup>
- A **high-protein, low-fat diet** allowing medium chain triglycerides is **first-line therapy**.<sup>1</sup>
- **Intravenous octreotide** and **absolute fasting with TPN for 4-12 weeks** are second-line therapies.<sup>1</sup>
- Refractory cases may call for more invasive therapies including **lymphatic duct glue** or **coil embolization, external beam radiation therapy, or surgical repair**.

## References

1. Kim J, Won JH. Percutaneous Treatment of Chylous Ascites. *Techniques in Vascular and Interventional Radiology*. December 2016. 19 (4): 291-8
2. Lizaola B, Bonder A, Trivedi HD, et al. Review article: the diagnostic approach and current management of chylous ascites. *Alimentary Pharmacology & Therapeutics*. September 2017. doi: 10.1111/apt.14284. Epub Ahead of Print.